Literature DB >> 20631646

Associations of proinflammatory cytokine levels with lipid profiles, growth, and body composition in HIV-infected children initiating or changing antiretroviral therapy.

Joseph S Cervia1, Caroline J Chantry, Michael D Hughes, Carmelita Alvero, William A Meyer, Janice Hodge, Peggy Borum, Jack Moye, Stephen A Spector.   

Abstract

OBJECTIVES: To measure proinflammatory cytokines (PIC) in HIV-infected children beginning or changing antiretroviral therapy (ART), evaluating associations with virologic, immunologic, serum lipid, growth, and body composition measures, markers of growth hormone action and glucose metabolism.
METHODS: Forty-nine prepubertal HIV-infected children had measurements of viral load (VL), CD4 lymphocyte count and percentage, serum lipids, apolipoprotein AI/B, IGF-1, IGFBP-1, and IGFBP-3, anthropometry, bioelectrical impedance analysis, TNF-α, IL-1 β, and IL-6 at baseline and 48 weeks of ART.
RESULTS: Baseline levels were detectable (>0.1 pg/mL) for IL-1 β in 28 of 48, and for TNF-α and Il-6 in all 49 children. TNF-α decreased with ART (P < 0.001) and IL-6 demonstrated a similar trend (P = 0.065). Children with 48-week VL <400 copies/mL had greater declines in TNF-α (mean 45%) than subjects with higher VL (5%; P = 0.009). Each 10% improvement in CD4% was associated with 26% lower TNF-α (P = 0.002) and 31% lower IL-6 (P = 0.016). Greater reductions in TNF-α were associated with lower total/HDL cholesterol ratio (P = 0.003) at week 48.
CONCLUSIONS: In HIV-infected children initiating or changing ART, PIC were detectable at baseline and decreased over 48 weeks. Better immunologic responses were associated with greater reductions in TNF-α and IL-6. Reductions in TNF-α were associated with improved total/HDL cholesterol ratio.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20631646      PMCID: PMC2991416          DOI: 10.1097/INF.0b013e3181ed9f4c

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  19 in total

1.  Decreases in plasma TNF-alpha level and IFN-gamma mRNA level in peripheral blood mononuclear cells (PBMC) and an increase in IL-2 mRNA level in PBMC are associated with effective highly active antiretroviral therapy in HIV-infected patients.

Authors:  P Brazille; N Dereuddre-Bosquet; C Leport; P Clayette; O Boyer; J-L Vildé; D Dormont; O Benveniste
Journal:  Clin Exp Immunol       Date:  2003-02       Impact factor: 4.330

2.  Prevalence of elevated cholesterol and associated risk factors among perinatally HIV-infected children (4-19 years old) in Pediatric AIDS Clinical Trials Group 219C.

Authors:  John Farley; Philimon Gona; Marilyn Crain; Joseph Cervia; James Oleske; George Seage; Jane Lindsey
Journal:  J Acquir Immune Defic Syndr       Date:  2005-04-01       Impact factor: 3.731

Review 3.  Micronutrient and cytokine interaction in congenital pediatric HIV infection.

Authors:  S Cunningham-Rundles; S H Kim; A Dnistrian; L Noroski; C Menendez-Botet; C B Grassey; G Hinds; J S Cervia
Journal:  J Nutr       Date:  1996-10       Impact factor: 4.798

4.  Growth, survival and viral load in symptomatic childhood human immunodeficiency virus infection.

Authors:  Caroline J Chantry; Robert S Byrd; Janet A Englund; Carol J Baker; Ross E McKinney
Journal:  Pediatr Infect Dis J       Date:  2003-12       Impact factor: 2.129

5.  Growth and body composition in children infected with the human immunodeficiency virus-1.

Authors:  T L Miller; S J Evans; E J Orav; V Morris; K McIntosh; H S Winter
Journal:  Am J Clin Nutr       Date:  1993-04       Impact factor: 7.045

6.  Tumor necrosis factor (TNF) system levels in human immunodeficiency virus-infected patients during highly active antiretroviral therapy: persistent TNF activation is associated with virologic and immunologic treatment failure.

Authors:  P Aukrust; F Müller; E Lien; I Nordoy; N B Liabakk; D Kvale; T Espevik; S S Froland
Journal:  J Infect Dis       Date:  1999-01       Impact factor: 5.226

7.  Natural history of somatic growth in infants born to women infected by human immunodeficiency virus. Women and Infants Transmission Study Group.

Authors:  J Moye; K C Rich; L A Kalish; A R Sheon; C Diaz; E R Cooper; J Pitt; E Handelsman
Journal:  J Pediatr       Date:  1996-01       Impact factor: 4.406

8.  Effect of human immunodeficiency virus infection on the growth of young children. Duke Pediatric AIDS Clinical Trials Unit.

Authors:  R E McKinney; J W Robertson
Journal:  J Pediatr       Date:  1993-10       Impact factor: 4.406

9.  Longitudinal assessment of growth in children born to mothers with human immunodeficiency virus infection.

Authors:  J M Saavedra; R A Henderson; J A Perman; N Hutton; R A Livingston; R H Yolken
Journal:  Arch Pediatr Adolesc Med       Date:  1995-05

10.  Cytokine profiles in human immunodeficiency virus-infected children treated with highly active antiretroviral therapy.

Authors:  Brian M Jones; Susan S S Chiu; Wilfred H S Wong; Wilina W L Lim; Yu-lung Lau
Journal:  MedGenMed       Date:  2005-05-03
View more
  12 in total

Review 1.  Unresolved antiretroviral treatment management issues in HIV-infected children.

Authors:  Shirin Heidari; Lynne M Mofenson; Charlotte V Hobbs; Mark F Cotton; Richard Marlink; Elly Katabira
Journal:  J Acquir Immune Defic Syndr       Date:  2012-02-01       Impact factor: 3.731

2.  HIV type 1 gp120-induced expansion of myeloid derived suppressor cells is dependent on interleukin 6 and suppresses immunity.

Authors:  Ankita Garg; Stephen A Spector
Journal:  J Infect Dis       Date:  2013-09-01       Impact factor: 5.226

3.  Safety and Efficacy of Atorvastatin in Human Immunodeficiency Virus-infected Children, Adolescents and Young Adults With Hyperlipidemia.

Authors:  Ann J Melvin; Grace Montepiedra; Lisa Aaron; William A Meyer; Hans M Spiegel; William Borkowsky; Mark J Abzug; Brookie M Best; Marilyn J Crain; Peggy R Borum; Bobbie Graham; Patricia Anthony; Katherine Shin; George K Siberry
Journal:  Pediatr Infect Dis J       Date:  2017-01       Impact factor: 2.129

4.  High prevalence of lipid abnormalities among antiretroviral-naive HIV-infected Asian children with mild-to-moderate immunosuppression.

Authors:  Suparat Kanjanavanit; Thanyawee Puthanakit; Ung Vibol; Pope Kosalaraksa; Rawiwan Hansudewechakul; Chaiwat Ngampiyasakul; Jurai Wongsawat; Wicharn Luesomboon; Jiratchaya Wongsabut; Apicha Mahanontharit; Tulathip Suwanlerk; Vonthanak Saphonn; Jintanat Ananworanich; Kiat Ruxrungtham
Journal:  Antivir Ther       Date:  2011

5.  Effect of Age at Antiretroviral Therapy Initiation on Catch-up Growth Within the First 24 Months Among HIV-infected Children in the IeDEA West African Pediatric Cohort.

Authors:  Julie Jesson; Sikiratou Koumakpaï; Ndeye R Diagne; Madeleine Amorissani-Folquet; Fla Kouéta; Addi Aka; Koko Lawson-Evi; Fatoumata Dicko; Kouadio Kouakou; Touré Pety; Lorna Renner; Tanoh Eboua; Patrick A Coffie; Sophie Desmonde; Valériane Leroy
Journal:  Pediatr Infect Dis J       Date:  2015-07       Impact factor: 2.129

6.  Dyslipidemia, chronic inflammation, and subclinical atherosclerosis in children and adolescents infected with HIV: The PositHIVe Health Study.

Authors:  Luiz Rodrigo Augustemak de Lima; Edio Luiz Petroski; Yara Maria Franco Moreno; Diego Augusto Santos Silva; Erasmo Benício de Moraes Santos Trindade; Aroldo Prohmann de Carvalho; Isabela de Carlos Back
Journal:  PLoS One       Date:  2018-01-10       Impact factor: 3.240

7.  Residual immune activation in HIV-Infected individuals expands monocytic-myeloid derived suppressor cells.

Authors:  Ritesh Singh; Mouli Chakraborty; Anuradha Gautam; Suman K Roy; Indranil Halder; Jamie Barber; Ankita Garg
Journal:  Cell Immunol       Date:  2021-02-10       Impact factor: 4.868

8.  Persistently lower bone mass and bone turnover among South African children living with well controlled HIV.

Authors:  Yanhan Shen; Stephanie Shiau; Renate Strehlau; Megan Burke; Faeezah Patel; Cara T Johnson; Bridgette Rizkalla; Gallagher Dympna; Louise Kuhn; Ashraf Coovadia; Michael T Yin; Stephen M Arpadi
Journal:  AIDS       Date:  2021-11-01       Impact factor: 4.632

9.  Inflammation-modulating cytokine profile and lipid interaction in HIV-related risk factors for cardiovascular diseases.

Authors:  Elizabeth Gori; Takafira Mduluza; Mudavanhu Nyagura; Babill Stray-Pedersen; Zvenyika Alfred Gomo
Journal:  Ther Clin Risk Manag       Date:  2016-11-11       Impact factor: 2.423

10.  Hepatic, Renal, Hematologic, and Inflammatory Markers in HIV-Infected Children on Long-term Suppressive Antiretroviral Therapy.

Authors:  Ann J Melvin; Meredith Warshaw; Alexandra Compagnucci; Yacine Saidi; Linda Harrison; Anna Turkova; Gareth Tudor-Williams
Journal:  J Pediatric Infect Dis Soc       Date:  2017-09-01       Impact factor: 3.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.